Medpace Holdings, Inc. (NASDAQ:MEDP) Stake Raised by Westover Capital Advisors LLC

Westover Capital Advisors LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,966 shares of the company’s stock after acquiring an additional 726 shares during the quarter. Westover Capital Advisors LLC’s holdings in Medpace were worth $1,522,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Los Angeles Capital Management LLC raised its position in Medpace by 47.7% in the fourth quarter. Los Angeles Capital Management LLC now owns 254,125 shares of the company’s stock worth $77,897,000 after acquiring an additional 82,068 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in Medpace by 44.4% during the 4th quarter. Benjamin Edwards Inc. now owns 358 shares of the company’s stock worth $110,000 after buying an additional 110 shares during the period. Victory Capital Management Inc. raised its holdings in Medpace by 21.5% during the 4th quarter. Victory Capital Management Inc. now owns 68,657 shares of the company’s stock worth $21,045,000 after buying an additional 12,127 shares during the period. Norden Group LLC raised its holdings in Medpace by 207.8% during the 4th quarter. Norden Group LLC now owns 5,014 shares of the company’s stock worth $1,537,000 after buying an additional 3,385 shares during the period. Finally, Van ECK Associates Corp raised its holdings in Medpace by 38.0% during the 4th quarter. Van ECK Associates Corp now owns 8,205 shares of the company’s stock worth $2,515,000 after buying an additional 2,258 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MEDP has been the topic of several recent analyst reports. Robert W. Baird boosted their price objective on Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective on the stock. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Finally, Guggenheim upped their target price on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $443.00.

Medpace Stock Down 1.1 %

Shares of MEDP traded down $4.21 during trading hours on Thursday, reaching $393.65. The company’s stock had a trading volume of 127,721 shares, compared to its average volume of 249,571. The firm has a market cap of $12.20 billion, a price-to-earnings ratio of 40.79, a P/E/G ratio of 1.93 and a beta of 1.40. The company has a 50 day moving average of $398.32 and a two-hundred day moving average of $328.94. Medpace Holdings, Inc. has a 1-year low of $197.39 and a 1-year high of $421.00.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating the consensus estimate of $2.45 by $0.75. The business had revenue of $511.00 million during the quarter, compared to analysts’ expectations of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The firm’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.27 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Insider Activity at Medpace

In other Medpace news, Director Ashley M. Keating sold 250 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the sale, the director now owns 250 shares of the company’s stock, valued at $102,467.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Medpace news, Director Ashley M. Keating sold 250 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the sale, the director now owns 250 shares of the company’s stock, valued at $102,467.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 204,442 shares of company stock valued at $82,702,867. 20.30% of the stock is owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.